Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma
10.3343/lmo.2020.10.2.109
- Author:
Kyunghoon LEE
1
;
In Young YOO
;
Jae-Won JOH
;
Jong Man KIM
;
Geum-Youn GWAK
;
Dong Hyun SINN
;
Sang Yun HA
;
Eun-Suk KANG
;
Hyung-Doo PARK
Author Information
1. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Laboratory Medicine Online
2020;10(2):109-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Liver cirrhosis is advanced stage of hepatic brosis caused by viral hepatitis. Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum marker to diagnose and evaluate hepatic brosis progression. In this study, we evaluated the efficacy of serum M2BPGi to predict chronic hepatitis B (HBV)-mediated cirrhosis by liver biopsy.
Methods:M2BPGi cut-off index (COI) was evaluated from 312 patients with chronic HBV-mediated hepatocellular carcinoma and 105 healthy controls. Comparative analysis was performed with conventional hepatic brosis markers such as brosis index based on four factors (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and Fibroscan.
Results:Korean Study Group for Pathology of Digestive Diseases classified 165 (52%) patients with histological stage F4 liver cirrhosis. Comparison of cases with stage F4 cirrhosis and stage F3 septal brosis revealed significant difference between M2BPGi, platelet count, APRI, FIB-4, and Fibroscan prediction. M2BPGi 2+ (COI ≥3) was found to be 8% in patients with F4 cirrhosis and 1% in patients with F3 brosis. In multi-regression analysis, M2BPGi showed higher odds ratio than that of other serum markers while M2BPGi 2+ showed comparable odds ratio to Fibroscan F3 and F4 assessment.
Conclusions:In patients with chronic HBV-mediated hepatocellular carcinoma, M2BPGi was neither comprehensive nor as effective as Fibroscan in assessing liver cirrhosis and brosis progression.
